Amelioration of free fatty acid-induced fatty liver by quercetin-3-O-β-D-glucuronide through modulation of peroxisome proliferator-activated receptor-alpha/sterol regulatory element-binding protein-1c signaling

Hepatology Research

Volumn 46, Issue 2, 2016, Pages 225-238

  Wang, Lu Lu ^a   Zhang, Zhi Chao ^a   Hassan, Waseem ^a   Li, Yu ^a   Liu, Jun ^a   Shang, Jing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Free fatty acid; Lipid accumulation; Non alcoholic fatty liver disease; Peroxisome proliferator activated receptor alpha; Quercetin 3 O D glucuronide; Sterol regulatory element binding protein 1c

Indexed keywords

BEZAFIBRATE; CARNITINE PALMITOYLTRANSFERASE I; FATTY ACID SYNTHASE; FLAVONOID; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUERCETIN 3 O BETA DEXTRO GLUCURONIDE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CPT1 GENE; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID OXIDATION; FATTY LIVER; FLOW CYTOMETRY; FREE FATTY ACID INDUCED FATTY LIVER; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIPOTOXICITY; LIVER CELL; LIVER WEIGHT; LOW DRUG DOSE; MALE; MCAD GENE; MOLECULAR DYNAMICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WEIGHT GAIN;

EID: 84958122868     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12557     Document Type: Article

References (51)

1. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006 (Sep); 131: 934-45.
2. Kirpich IA, McClain CJ. Probiotics in the treatment of the liver diseases. J Am Coll Nutr 2012; 31: 14-23.
3. Tilg H, Moschen AR. Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis. Hepatology 2010; 52: 1836-46.
4. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010; 5: 145-71.
5. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-51.
6. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-25(e6).
7. Ibrahim SH, Kolhi R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr 2011; 53: 131-40.
8. Pan MH, Lai S, Tsai L et al. Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. Mol Nutr Food Res 2014; 58: 147-71.
9. Aoyama T, Peters JM, Iritani N etal. Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor (PPAR ). J Biol Chem 1998; 273: 5678-84.
10. Nakajima T, Kamijo Y, Tanaka N etal. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 2004 (Oct); 40: 972-80.
11. Kamijo Y, Hora K, Kono K etal. PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol : JASN 2007 (Dec); 18: 3089-100.
12. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 2012 (May); 1821: 809-18.
13. Repa JJ, Liang G, Ou J etal. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors. LXRalpha and LXRbeta Genes dev 2000 (Nov 15); 14: 2819-30.
14. Ahmed MH, Byrne CD. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today 2007; 12: 740-7.
15. Xu L, Kim JK, Bai Q etal. 5-cholesten-3β, 25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model. Mol Pharmacol 2013; 83: 648-658.
16. Bai Q, Zhang X, Xu L etal. Oxysterol Sulfation by SULT2B1b Suppresses LXR/SREBP-1c Signaling Pathway and Reduces Serum and Hepatic Lipids in Mouse Models of NAFLD. Metabolism 2012; 61: 836-45.
17. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proceedings of the National Academy of Sciences of the United States of America. 2004;101: págs. 11245-50.
18. Terao J. Dietary flavonoids as antioxidants. Forum Nutr 2009; 61: 87-94.
19. Ishizawa K, Yoshizumi M, Kawai Y etal. Pharmacology in Health Food: Metabolism of Quercetin In Vivo and Its Protective Effect Against Arteriosclerosis. J Pharmacol Sci 2011; 115: 466-70.
20. Fan D, Zhou X, Zhao C, Chen H, Zhao Y, Gong X. Anti-inflammatory, antiviral and quantitative study of quercetin-3-O-beta-D-glucuronide in Polygonum perfoliatum L. Fitoterapia 2011 (Sep); 82: 805-10.
21. Hong EJ, Levasseur MP, Dufour CR, Perry MC, Giguere V. Loss of estrogen-related receptor alpha promotes hepatocarcinogenesis development via metabolic and inflammatory disturbances. Proc Natl Acad Sci U S A 2013 (Oct 29); 110: 17975-80.
22. Gunduz F, Aboulnasr FM, Chandra PK etal. Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture. Virol J 2012; 9: 143.
23. Akazawa Y, Cazanave S, Mott JL etal. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol 2010 (Apr); 52: 586-93.
24. Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Castell JV, O'Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 2007 (Jan 30); 165: 106-16.
25. Yamasaki M, Chujo H, Nou S, Tachibana H, Yamada K. Alleviation of the cytotoxic activity induced by trans10, cis12-conjugated linoleic acid in rat hepatoma dRLh-84 cells by oleic or palmitoleic acid. Cancer Lett 2003 (Jul 10); 196: 187-96.
26. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 (Jun); 41: 1313-21.
27. Bustin SA, Benes V, Garson JA etal. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009 (Apr); 55: 611-22.
28. Wu X, Zhang L, Gurley E etal. Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 2008 (Jun); 47: 1905-15.
29. Tanaka T, Masuzaki H, Ebihara K etal. Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice. Metab: clin exp 2005 (Nov); 54: 1490-8.
30. Pawlak M, Lefebvre P, Staels B. Molecular Mechanism of PPARα Action and its Impact on Lipid Metabolism, Inflammation and Fibrosis in Non-Alcoholic Fatty Liver Disease. J Hepatol 2015; 62: 720-733.
31. Lu Y, Liu X, Jiao Y etal. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J Clin Invest 2014; 124: 3501.
32. Bechmann LP, Vetter D, Ishida J etal. Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol 2013 (May); 58: 1000-6.
33. Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 2011 (Apr 1); 141: 603-10.
34. Peters JM, Aoyama T, Burns AM, Gonzalez FJ. Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice. Biochimica et Biophysica Acta (BBA) - Mol Cell Biol Lipids 2003; 1632: 80-9.
35. Nagasawa T, Inada Y, Nakano S etal. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006 (Apr 24); 536: 182-91.
36. Ferre P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010; 12 (Suppl 2): 83-92.
37. Ai ZL, Zhu CH, Min M etal. The role of hepatic liver X receptor alpha- and sterol regulatory element binding protein-1c-mediated lipid disorder in the pathogenesis of non-alcoholic steatohepatitis in rats. J Int Med Res 2011; 39: 1219-29.
38. Han JY, Park SH, Yang JH etal. Licochalcone Suppresses LXRα-Induced Hepatic Lipogenic Gene Expression through AMPK/Sirt1 Pathway Activation. Toxicol Res 2014; 30: 19-25.
39. Kim YW, Kim YM, Yang YM etal. Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis. Free Radic Biol Med 2010 (Feb 15); 48: 567-78.
40. Yoshikawa T, Ide T, Shimano H etal. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Mol Endocrinol 2003 (Jul); 17: 1240-54.
41. Ide T, Shimano H, Yoshikawa T et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol Endocrinol 2003; 17: 1255-67.
42. Miyata KS, McCaw SE, Patel HV, Rachubinski RA, Capone JP. The Orphan Nuclear Hormone Receptor LXR Interacts with the Peroxisome Proliferator-activated Receptor and Inhibits Peroxisome Proliferator Signaling. J Biol Chem 1996; 271: 9189-9192.
43. Goldwasser J, Cohen PY, Yang E, Balaguer P, Yarmush ML, Nahmias Y. Transcriptional Regulation of Human and Rat Hepatic Lipid Metabolism by the Grapefruit Flavonoid Naringenin: Role of PPARα. PPARγ and LXRα PloS one 2010; 5: e12399.
44. Hu XQ, Wang YM, Wang JF etal. Dietary saponins of sea cucumber alleviate orotic acid-induced fatty liver in rats via PPARalpha and SREBP-1c signaling. Lipids Health Dis 2010; 9: 25.
45. Ziamajidi N, Khaghani S, Hassanzadeh G et al. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. Food Chem Toxicol 2013; 58: 198-209.
46. Ronis MJ, Chen Y, Badeaux J, Badger TM. Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling. J Nutr 2009; 139; 1431-1438.
47. Ali F, Ismail A, Kersten S. Molecular mechanisms underlying the potential antiobesity-related diseases effect of cocoa polyphenols. Mol Nutr Food Res 2014 (Jan); 58: 33-48.
48. Marcolin E, San-Miguel B, Vallejo D etal. Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J Nutr 2012 (Oct); 142: 1821-8.
49. Guo XD, Zhang DY, Gao XJ etal. Quercetin and quercetin-3-O-glucuronide are equally effective in ameliorating endothelial insulin resistance through inhibition of reactive oxygen species-associated inflammation. Mol Nutr Food Res 2013 (Jun); 57: 1037-45.
50. Alberdi G, Rodríguez VM, Miranda J, Macarulla MT, Churruca I, Portillo MP. Thermogenesis is involved in the body-fat lowering effects of resveratrol in rats. Food Chem 2013; 141: 1530-5.
51. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005; 4 (14): 1-5.